Valneva (NASDAQ: VALN) details access to 2026 Annual General Meeting documents

Rhea-AI Filing Summary

Valneva SE has made the documentation for its Annual General Meeting on June 25, 2026 available to shareholders. The meeting will be held in Lyon, France, at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel.

Shareholders can access the agenda, draft resolutions, and voting instructions on Valneva’s website, or request them by email in line with French Commercial Code rules. Bearer shareholders must provide a shareholding certificate. The company also reiterates its focus on specialty vaccines and includes standard forward-looking statement cautions.

Key Figures

AGM date and time: June 25, 2026, 2:00 p.m. CEST Preliminary notice publication date: May 18, 2026

2 metrics

AGM date and time June 25, 2026, 2:00 p.m. CEST Scheduled Annual General Meeting in Lyon, France

Preliminary notice publication date May 18, 2026 Notice published in BALO

Key Terms

Annual General Meeting, Bulletin des Annonces Légales Obligatoires, bearer shares, forward-looking statements, +1 more

5 terms

Annual General Meeting financial

"documentation for its Annual General Meeting (“the Meeting”) to be held on June 25, 2026"

Bulletin des Annonces Légales Obligatoires regulatory

"was published in the Bulletin des Annonces Légales Obligatoires (BALO) on May 18, 2026"

bearer shares financial

"Holders of bearer shares may exercise this right on the condition that they provide a shareholding certificate"

Bearer shares are physical share certificates that make whoever holds the paper the legal owner, like cash that transfers ownership simply by passing hands. They matter to investors because they allow fast, anonymous transfer but also carry extra risks: loss or theft can mean losing ownership, and many regulators restrict or ban them for tax, anti-money‑laundering and transparency reasons, which can affect legality, tradability and due diligence for investments.

forward-looking statements regulatory

"This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

French Commercial Code regulatory

"in accordance with the provisions of Article R. 225-88 of the French Commercial Code"

The French Commercial Code is the national rulebook that sets the legal framework for business activity in France, covering company formation and governance, commercial contracts, trade practices, bankruptcy procedures and the role of commercial courts. For investors, it matters because these rules determine how companies are structured, how contracts and disputes are handled, and how creditor and shareholder rights are protected — like an operating manual that shapes business risk and legal recourse.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report: June 4, 2026

Commission File Number: 001-40377

Valneva SE

(Translation of registrant's name into English)

Îlot Saint-Joseph, Bureaux Convergence

12ter Quai Perrache

69002 Lyon, France

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On June 4, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1. The information contained in this Form 6-K is hereby incorporated by reference into the registrant's registration Statement on Form F-3 (File No. 333-268071).

Exhibit
Exhibit 99.1			Press release dated June 4, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Valneva SE (Registrant)

Date: June 4, 2026

/s/ Thomas Lingelbach

Thomas Lingelbach

Chief Executive Officer and President

Valneva Announces Availability of Documentation for its Annual General Meeting

Lyon (France), June 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Annual General Meeting (“the Meeting”) to be held on June 25, 2026 at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel, 20 quai du Docteur Gailleton, 69002 Lyon (France).

The Preliminary Notice of Meeting – including the agenda, the draft resolutions proposed by the Board of Directors, and instructions for participation and voting to the Meeting – was published in the Bulletin des Annonces Légales Obligatoires (BALO) on May 18, 2026.

The information and preparatory documents related to this Meeting are available on Valneva’s website via https://valneva.com/june-25-2026-annual-general-meeting/.

Therefore, shareholders are invited to consult these documents and information online or, if desired, to request that they be sent by email, in accordance with the provisions of Article R. 225-88 of the French Commercial Code (as amended by Decree No. 2026-94 dated February 13, 2026).

Any shareholder wishing to receive these Meeting documents by e-mail may make a request until the fifth day inclusive before the Meeting date, by contacting the Company at assemblee.generale@valneva.com. Holders of bearer shares may exercise this right on the condition that they provide a shareholding certificate certifying the registration of the shares in a bearer securities account managed by an authorized financial intermediary.

Shareholders may also access the Meeting documentation at the Company’s registered office in Lyon.

About Valneva SE

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.

We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.

Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at www.valneva.com.

VALNEVA SE

Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP, Global Communications and European Investor Relations M +33 (0)6 4516 7099 laetitia.bachelotfontaine@valneva.com Joshua Drumm, Ph.D. VP, Global Investor Relations M +001 917 815 4520 joshua.drumm@valneva.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in France. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements with respect to: future financial performance and financial guidance including projected product sales, total revenue and total R&D investments; Valneva’s plans for investment in future growth; the timing of orders for commercial products; plans and expectations regarding the development, commercialization and commercial prospects of Valneva’s product candidates and commercial products, including the prospects and timing of actions relating to clinical studies and trials and product approvals, such as study initiations, study advancements, data readouts, submissions, filings, approvals, and label expansions; the expected benefits and availability of Valneva’s commercial products and product candidates; and potential growth opportunities and trends, including the assumptions and expectations regarding total market opportunity targeted by Valneva’s product candidates and commercial products. These forward-looking statements are based on Valneva’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Valneva’s business, strategy, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: Valneva’s success in the commercialization of its commercial products; uncertainties and delays involved in the development and manufacture of vaccines; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including tariffs and other trade policies, the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and uncertain credit and financial markets, on Valneva’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; Valneva’s ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; the impact of the global and European credit crisis; the ability to obtain or maintain patent or other proprietary intellectual property protection and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking

2

statements in this press release are identified in the section titled “Risk Factors” in Valneva’s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (“SEC”) and the Autorité des marchés financiers (“AMF”) on March 18, 2026, and in other filings made with the SEC and AMF from time to time. Valneva is providing this information as of the date of this press release and expressly disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

3

FAQ

When is Valneva (VALN) holding its June 25, 2026 Annual General Meeting?

Valneva will hold its Annual General Meeting on June 25, 2026 at 2:00 p.m. CEST in Lyon, France. The event will take place at the Sofitel Lyon Bellecour Hotel, where shareholders can vote on resolutions proposed by the Board of Directors.

How can Valneva shareholders access the 2026 Annual General Meeting documents?

Shareholders can access the Annual General Meeting documents on Valneva’s website via the dedicated meeting page. They may also request the documents by email in accordance with Article R. 225-88 of the French Commercial Code, within the specified deadline before the meeting.

What information is included in Valneva’s 2026 Annual General Meeting documentation?

The AGM documentation includes the agenda, draft resolutions proposed by the Board of Directors, and instructions for participation and voting. These preparatory documents help shareholders understand the matters to be decided and how they can exercise their voting rights at the meeting.

What must bearer shareholders of Valneva (VALN) provide to receive AGM documents by email?

Bearer shareholders must provide a shareholding certificate confirming that their Valneva shares are registered in a bearer securities account managed by an authorized financial intermediary. This proof is required when they request to receive the Annual General Meeting documentation by email from the company.

Where was the preliminary notice for Valneva’s June 25, 2026 AGM published?

The preliminary notice of Valneva’s Annual General Meeting, including the agenda and draft resolutions, was published in the Bulletin des Annonces Légales Obligatoires (BALO) on May 18, 2026. This official publication informs shareholders about the upcoming meeting and key procedural details.

What does Valneva highlight about its business in this 6-K filing?

Valneva highlights that it is a specialty vaccine company developing and commercializing prophylactic vaccines for infectious diseases with unmet medical needs. It notes three proprietary travel vaccines on the market and a pipeline including advanced candidates for Lyme disease and Shigella.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 15.8 KB